Medications Used Among Nonhospitalized Pregnant Women With COVID ‐19: A Prospective Individual Patient Data Meta‐Analysis in Europe and North America
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70303 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Odette de Bruin und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Medicines Agency (EMA), Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation (CFI).
Abstract (Originalsprache)
Aim
To estimate the prevalence of medication use in nonhospitalized pregnant women with COVID‐19.
Methods
A prospective two‐stage individual patient meta‐analysis across 10 data sources in Europe and North America studied medication use among nonhospitalized pregnant women with COVID‐19 between January 2020 and December 2022. Comparisons were made between medication use within 30 days pre‐ and post‐COVID‐19 diagnosis in this cohort and two comparator groups: pregnant women without COVID‐19 and nonpregnant women with COVID‐19. Prevalence estimates were pooled using a random‐effects model stratified by trimester.
Results
50 335 nonhospitalized pregnant women with COVID‐19 were identified. The pooled prevalence of antibacterial use in the third trimester was higher post‐COVID‐19 diagnosis (6.8%, 95% confidence interval [CI] = 5.5–8.4, I 2 = 94%) compared with the same women pre‐COVID‐19 (3.9%, 95% CI = 3.1–4.9, I 2 = 89%). Overall, pregnant women with COVID‐19 had higher medication use compared to pregnant women without COVID‐19, although the CIs of the prevalence overlapped. Post‐COVID‐19, antithrombotic prevalence was 4.5% (95% CI = 1.1–16.5, I 2 = 100%) among pregnant women with COVID‐19 in the third trimester, compared to 2.1% (95% CI = 1.2–3.6, I 2 = 99%) among those without COVID‐19 in the third trimester. Compared to nonpregnant women with COVID‐19, pregnant women with COVID‐19 were less likely to be prescribed analgesics, antiprotozoals, corticosteroids, psychoanaleptics and psycholeptics, and more likely to be prescribed antithrombotics, cough and cold and nasal preparations, and drugs used in diabetes across all trimesters. High heterogeneity existed in nearly all analyses.
Conclusion
This international meta‐analysis reveals low medication use and country‐specific variations, enhancing insight into the management of COVID‐19 in nonhospitalized pregnant women. Higher antithrombotic use post‐COVID‐19 suggests prophylactic treatment in this population, but variation between countries emphasizes the challenges of combining multinational data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands.
- Department of Obstetrics, Division of Woman and Baby, Wilhelmina Children's Hospital, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands.
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
- Graduate School for Health Sciences (GHS), University of Bern, Bern, Switzerland.
- Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital, Lausanne, Switzerland.
- Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo (UiO), Oslo, Norway.
ORCID-Profile: Odette de Bruin, Emeline Maisonneuve, Eimir Hurley, Hedvig M E Nordeng, Anick Bérard, Odile Sheehy, Padma Kaul, José J Hernández-Muñoz, Leyla Sahin, Carolyn E Cesta, David Hägg, Rosa Gini, Clara L Rodríguez-Bernal, Guillaume Favre, Alice Panchaud, Kitty W M Bloemenkamp, Satu J Siiskonen, Miriam C J M Sturkenboom
Förderung
- European Medicines Agency (EMA)
- Canadian Institutes of Health Research (CIHR)
- Canada Foundation for Innovation (CFI)
- U.S. Food and Drug Administration (FDA)
Zitieren
APA
de Bruin, O., Maisonneuve, E., Hurley, E., Nordeng, H. M. E., Bérard, A., Sheehy, O., Kaul, P., Shinde, M. U., Cosgrove, A., Lyons, J. G., Messenger-Jones, E., Kempner, M. E., Toh, S., Hua, W., Hernández-Muñoz, J. J., Sahin, L., Cesta, C. E., Hägg, D., Gini, R., …, & CONSIGN Collaboration Group (2026). Medications Used Among Nonhospitalized Pregnant Women With COVID ‐19: A Prospective Individual Patient Data Meta‐Analysis in Europe and North America. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70303
Vancouver
de Bruin O, Maisonneuve E, Hurley E, Nordeng HME, Bérard A, Sheehy O, et al. Medications Used Among Nonhospitalized Pregnant Women With COVID ‐19: A Prospective Individual Patient Data Meta‐Analysis in Europe and North America. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70303
BibTeX
@article{deBruin2026,
author = {de Bruin, Odette and Maisonneuve, Emeline and Hurley, Eimir and Nordeng, Hedvig M E and Bérard, Anick and Sheehy, Odile and Kaul, Padma and Shinde, Mayura U and Cosgrove, Austin and Lyons, Jennifer G and Messenger-Jones, Elizabeth and Kempner, Maria E and Toh, Sengwee and Hua, Wei and Hernández-Muñoz, José J and Sahin, Leyla and Cesta, Carolyn E and Hägg, David and Gini, Rosa and Paoletti, Olga and Poblador-Plou, Beatriz and Jordan, Sue and Thayer, Daniel and Rodríguez-Bernal, Clara L and Sánchez-Sáez, Francisco and Lassalle, Régis and Bernard, Marie-Agnès and Alsina, Ema and Ahmadizar, Fariba and Favre, Guillaume and Panchaud, Alice and Bloemenkamp, Kitty W M and Plueschke, Kelly and de Vries, Corinne and Siiskonen, Satu J and Sturkenboom, Miriam C J M and CONSIGN Collaboration Group, CONSIGN Collaboration Group},
title = {Medications Used Among Nonhospitalized Pregnant Women With COVID ‐19: A Prospective Individual Patient Data Meta‐Analysis in Europe and North America},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70303}
}
EUVIMED